NASDAQ:FIXX - Homology Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$24.57 +0.71 (+2.98 %)
(As of 01/16/2019 04:00 PM ET)
Previous Close$23.86
Today's Range$23.85 - $24.89
52-Week Range$15.07 - $26.50
Volume58,800 shs
Average Volume146,291 shs
Market Capitalization$891.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Current Ratio13.24
Quick Ratio13.24

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A

Profitability

Net Income$-29,990,000.00
Net MarginsN/A
Return on Assets-24.90%

Miscellaneous

Employees67
Market Cap$891.28 million
OptionableNot Optionable

Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) posted its earnings results on Tuesday, November, 13th. The company reported ($0.40) EPS for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.03. The firm earned $0.95 million during the quarter. View Homology Medicines' Earnings History.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, February 12th 2019. View Earnings Estimates for Homology Medicines.

What price target have analysts set for FIXX?

6 analysts have issued 1 year price objectives for Homology Medicines' shares. Their predictions range from $18.50 to $37.00. On average, they expect Homology Medicines' share price to reach $29.50 in the next year. This suggests a possible upside of 20.1% from the stock's current price. View Analyst Price Targets for Homology Medicines.

What is the consensus analysts' recommendation for Homology Medicines?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Has Homology Medicines been receiving favorable news coverage?

News articles about FIXX stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Homology Medicines earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future.

Who are some of Homology Medicines' key competitors?

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the folowing people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 55)
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 62)
  • Mr. Albert Seymour Ph.D., Chief Scientific Officer (Age 50)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Dr. Siyamak Rasty Ph.D., Chief Operating Officer (Age 54)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $24.57.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $891.28 million. Homology Medicines employs 67 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is http://www.homologymedicines.com.

How can I contact Homology Medicines?

Homology Medicines' mailing address is One Patriots Park, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.


MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  72
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel